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Cystatin C levels are unaltered in
patients with diabetes mellitus
and normal renal function
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To the Editor: In their recent article, Stevens et al.1 have
reported that factors other than glomerular filtration rate
(GFR) affect serum cystatin C (CysC) levels. Specifically,
they mentioned the impact of diabetes mellitus, which was
associated with 8.5% higher levels of CysC. However,
proteinuria was also associated with CysC and, as admitted
by the authors, diabetes and proteinuria were strongly
associated in their patient cohorts. Thus, their data did not
allow for determining the independent effects of diabetes
mellitus or proteinuria. We have previously reported GFR
data of a cohort of patients with normo-albuminuric diabetes
type I and age- and sex-matched controls.2 From this cohort,
we have selected 33 patients and 38 controls with matching
GFR (inulin clearance) and evaluated the relationship
between CysC and GFR.
At baseline, the mean GFR was 112±9ml/min per 1.73m2
and mean CysC was 0.68±0.1mg/l. In univariable regression
analysis, age (P¼ 0.016), gender (P¼ 0.001), serum albumin
(P¼ 0.001), and serum urea (P¼ 0.002) significantly influ-
enced the relationship of CysC with GFR. Diabetes was not a
predictor of this relationship (Figure 1). In multivariable
analysis age (P¼ 0.003), gender (P¼ 0.007), and serum urea
(P¼ 0.004) remained independent predictors.
In our cohort of type I diabetic patients with normal renal
function without proteinuria, we could not confirm the
influence of diabetes on the relationship between CysC
and GFR. The effect, as found by Stevens et al.,1 may be due
to the interaction with proteinuria, which was present in
the majority of their patients.
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To the Editor: Changing the chronic kidney disease (CKD)
staging system, as proposed by Winearls and Glassock,1 could
have a negative impact on prevention. One of the hardest
tasks faced by a nephrologist is breaking the news about
imminent dialysis to an unsuspecting patient. This gets ever
more painful if early signs of kidney disease, such as a mildly
depressed glomerular filtration rate (eGFR), were somehow
uncovered in the past but the patient was reassured without
further testing and sent home only to learn otherwise at a
later date. Bad as it seems, this is a recurrent experience for
any nephrologist. Therefore, we were concerned with this
proposition to revise the Kidney Disease Outcomes Quality
Initiative (KDOQI) staging system of CKD and eliminate the
current early stages of the system. Although we recognize that
a proportion of healthy individuals may be transitorily
mislabeled as CKD patients, we believe that it is better to
raise the possibility of incipient CKD and discard it afterward
than to miss diagnosis by not looking for it. The current
staging system of CKD has been very successful in bringing
worldwide uniformity to the nomenclature and has met the
goal of raising awareness within the renal and nonrenal
medical communities to new levels. Rather than a matter of
opinion, this is a ripe area for scientific inquiry. We challenge
the renal community, as would be the case with any new
classification system, to use tools of diagnostic statistics and
to determine the predictive values of KDOQI staging within
the different categories so that we can act and inform our
patients appropriately.
However, we do not disagree that a minor review of CKD
staging may be in order. The wide range of GFR that defines
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Figure 1 |Relationship between Cystatin C levels and
glomerular filtration rate (inulin clearance). Diabetes does not
influence this relationship.
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stage 3 (30–59ml/min per 1.73m2) implies that a person with
a GFR of 55ml/min per 1.73m2 would have a potential for
complications similar to that of someone with a GFR of
35ml/min. For example, it has recently been shown that
patients with CKD and GFR o45ml/min per 1.73m2,
particularly the older patients, experience faster disease
progression.2 We suggest that it would be clinically sound
to subdivide stage 3 into stages 3A (45–59ml/min) and 3B
(30–44ml/min), as these two ranges may be associated
with different clinical patterns and risks. Patients with
stage 3B should probably be referred earlier to specialized
renal care.
Finally, the classification proposed by the authors using
percentiles to determine ranges of renal function is not easily
applicable in clinical practice. We contend that a change in a
system successfully used at this moment may cause
disorientation in the medical community and undermine
our credibility. Present staging has preventive and epidemio-
logical roles; additional tools can be used and developed
specifically for research aims, but the contribution to
nephrology practice of the current staging system and the
widespread use of eGFR formulae should not be reverted.
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We agree that informing unsuspecting patients that they
have irreversible ESRD (end-stage renal disease) that
requires quick or immediate renal replacement is difficult,
and that the task is more awkward if the situation could
have been prevented or at least predicted. Kirsztajn et al.1
imply that this, their ‘hardest task,’ can be avoided by the
use of the Kidney Disease Outcomes Quality Initiative
(KDOQI) staging system. We disagree.
In the United Kingdom, in 2007, late presentation of
ESRD, also inaccurately called ‘late referral,’ occurred in
21% of the 109 per million population (pmp) new patients
starting renal replacement, which translates to B21 pmp
‘late presenters’ per year.2 If one excludes those patients in
whom renal failure and the need for renal replacement
could not have been predicted (such as patients with
multiple myeloma, vasculitis, catastrophic irreversible
acute renal failure, and malignancy), the figure for
avoidable late presentation is much lower. Indeed, in
2007, in the Oxford kidney unit, there was a missed
opportunity for earlier referral in only 5% of the 150 new
patients. The KDOQI staging system would have us believe
that 130,000 individuals pmp have chronic kidney disease
(CKD). Even if the system could prevent ‘late referral’
(there is no evidence that it does), the labeling of so large a
number to identify the 1 in 26,000 CKD patients or 5 per
million of the general population who are referred late is
not justified. The ‘NNT’ becomes not a ‘number needed to
treat,’ but a ‘number needed to terrify.’ In health systems
with poor communication between primary and secondary
care, the problem of ‘late referral’ may be greater, but it
could be solved by educating primary care physicians
about identifying those at risk of progressive CKD and
how to interpret an abnormal creatinine level.
We do not advocate eliminating the early stages of CKD
from the system but rather tightening the definition of
kidney disease and amalgamating stages 1 and 2, which
cannot reliably be distinguished by the Modification of
Diet in Renal Disease Study equation for estimated
glomerular filtration rate (eGFR).3
Kirsztajn et al. and others also recognize that stage 3 is
not homogeneous.4,5 In the United Kingdom, the National
Institute for Clinical Excellence suggests subdividing this
stage into no less than 4 subcategories, based on whether
the eGFR is less or greater than 45 ml/min per m2 and the
presence or absence of proteinuria.6 This is a clear
admission that the label ‘stage 3 CKD’ is an unsatisfactory
and misleading description as pointed out by Kirsztajn
et al. Moreover, stage 3 in a 1–5 staging system is halfway to
the very end point (ESRD) that they find so painful to
discuss and yet, only 0.4% of patients so classified progress
to ESRD per annum.7
We are unconvinced by their argument that a change in
the staging system would confuse the medical community.
Non-nephrologists are already mystified by the so-called
epidemic of CKD in their midst, and there are a growing
number of calls to correct it.8 If it is wrong, we should
admit it and modify it before it becomes embedded in
medical thinking. How would medicine ever progress
if we accepted theories as truths for fear of causing
confusion?
We are also unconvinced that doctors would have
difficulty in using percentile charts––they do so quite
comfortably for assessing growth in children, bone
mineral density, and the risks of hyperlipidemia. Indeed,
we use the ‘Wetzels’ charts to reassure patients that their
eGFRs, although lower than the normal of 90 ml/min per
1.72 m2 asserted by the KDOQI, are in the range for
healthy individuals of their age and gender.9
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